Effect of alpha-1 antitrypsin Portland variant (alpha 1-PDX) on HIV-1 replication

Area of Science:

• Virology
• Biochemistry
• Immunology

Background:

• Human immunodeficiency virus type 1 (HIV-1) replication involves complex viral machinery.
• Viral-induced syncytia formation is a hallmark of HIV-1 cytopathic effects.
• Serine proteinase inhibitors (serpins) are being explored for antiviral properties.

Purpose of the Study:

• To investigate the potential of alpha-1 antitrypsin Portland variant (alpha 1-PDX) to inhibit HIV-1 replication.
• To determine if alpha 1-PDX affects HIV-1 induced syncytia formation.
• To analyze the impact of alpha 1-PDX on HIV-1 envelope glycoprotein maturation.

Main Methods:

• Stable transfection of Jurkat cells with alpha 1-PDX cDNA (J-PDX) or control vector (J-pcDNA3).
• Infection of J-PDX and J-pcDNA3 cells with HIV-1(Lai).
• Assessment of viral replication kinetics, infectious capacity, syncytia formation, and viral protein maturation (gp160 to gp120/gp41) via Western blotting and densitometry.

Main Results:

• Alpha 1-PDX significantly inhibited HIV-1 replication and delayed replication kinetics in J-PDX cells compared to controls.
• Alpha 1-PDX interfered with syncytia formation between infected and uninfected cells.
• Inhibition of viral replication and cytopathic effects correlated with alpha 1-PDX's interference in gp160 maturation to gp120 and gp41.

Conclusions:

• Alpha 1-PDX demonstrates significant antiviral activity against HIV-1.
• Alpha 1-PDX inhibits HIV-1 replication by interfering with viral glycoprotein maturation and syncytia formation.
• Alpha 1-PDX represents a potential therapeutic agent for HIV-1 infection.